The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)

MLA

M.Al Ghobain, et al. “The Efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in Adult Patients with Moderate COVID-19 Pneumonia (Pilot Randomized Clinical Trial).” Journal of Infection and Public Health, vol. 15, no. 12, Dec. 2022, pp. 1546–50. EBSCOhost, https://doi.org/10.1016/j.jiph.2022.11.016.

APA

M.Al Ghobain, F. Rebh, A. Saad, A.H. Khan, N. Mehyar, A. Mashhour, I. Islam, Y. Alobaida, A.S. Alaskar, M. Boudjelal, & M.Al Jeraisy. (2022). The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial). Journal of Infection and Public Health, 15(12), 1546–1550. https://doi.org/10.1016/j.jiph.2022.11.016

Chicago

M.Al Ghobain, F. Rebh, A. Saad, A.H. Khan, N. Mehyar, A. Mashhour, I. Islam, et al. 2022. “The Efficacy of Zafirlukast as a SARS-CoV-2 Helicase Inhibitor in Adult Patients with Moderate COVID-19 Pneumonia (Pilot Randomized Clinical Trial).” Journal of Infection and Public Health 15 (12): 1546–50. doi:10.1016/j.jiph.2022.11.016.